10-QPeriod: Q2 FY2017

DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2017

Filed August 1, 2017For Securities:DXCM

Summary

DEXCOM INC (DXCM) reported its second-quarter and first-half 2017 financial results, showcasing significant revenue growth driven by increased sales volume of its continuous glucose monitoring (CGM) systems. While the company continues to operate at a net loss, the financial performance indicates progress in scaling operations and expanding market reach. A key development during the quarter was the successful issuance of convertible senior notes, significantly bolstering the company's cash position and providing resources for future growth initiatives, including manufacturing expansion and potential acquisitions. The company also highlighted its ongoing efforts to secure broader insurance reimbursement, a critical factor for sustained commercial success. Operationally, revenue increased by 24.3% year-over-year for the three months ended June 30, 2017, reaching $170.6 million, and by 23.4% for the six months ended June 30, 2017, to $312.9 million. Despite this top-line growth, operating expenses, particularly in research and development and selling, general, and administrative functions, also increased as the company invests in product development and market penetration. The company ended the period with a substantially improved cash balance, largely due to the convertible note issuance, and expressed confidence in its ability to fund operations through at least June 30, 2018.

Financial Statements
Beta
Revenue$170.60M
Cost of Revenue$53.10M
Gross Profit$117.50M
R&D Expenses$45.30M
SG&A Expenses$85.80M
Operating Expenses$131.10M
Operating Income-$13.60M
Interest Expense$3.10M
Net Income$2.90M
EPS (Basic)$0.01
EPS (Diluted)$0.01
Shares Outstanding (Basic)345.60M
Shares Outstanding (Diluted)349.60M

Key Highlights

  • 1Revenue for the second quarter of 2017 increased to $170.6 million, a 24.3% rise compared to $137.3 million in the same period last year, driven by higher sales volume of disposable sensors and durable CGM systems.
  • 2For the six months ended June 30, 2017, revenue grew by 23.4% to $312.9 million, up from $253.5 million in the prior year's comparable period.
  • 3The company significantly strengthened its cash position by issuing $400 million in convertible senior notes, with net proceeds of $389.0 million, used in part to repay borrowings and for general corporate purposes.
  • 4Gross profit margin improved to 69% in Q2 2017 from 62% in Q2 2016, attributed to increased revenue and a decrease in warranty costs.
  • 5Research and Development expenses increased by $9.0 million in Q2 2017 to $45.3 million, and Selling, General, and Administrative expenses rose by $16.5 million to $85.8 million, reflecting investments in growth and commercialization.
  • 6The company reported a net loss for both the three months ended June 30, 2017 ($2.9 million) and the six months ended June 30, 2017 ($38.8 million), although the net loss narrowed in the three-month period compared to the prior year's loss of $20.2 million.
  • 7Cash and cash equivalents increased substantially to $395.9 million as of June 30, 2017, from $94.5 million at the end of 2016, primarily due to the convertible note issuance.

Frequently Asked Questions

DexCom reported revenue of $170.6 million for the three months ended June 30, 2017, an increase of 24.3% compared to $137.3 million in the same period of 2016. This growth was primarily driven by increased sales volume of their disposable sensors and durable continuous glucose monitoring (CGM) systems.

DexCom significantly enhanced its liquidity by completing an offering of $400 million in aggregate principal amount of 0.75% convertible senior notes due 2022. The net proceeds of approximately $389.0 million provided substantial cash for general corporate purposes, capital expenditures, and repayment of existing debt, boosting their cash and cash equivalents to $395.9 million by the end of the quarter.

For the three months ended June 30, 2017, DexCom reported a net income of $2.9 million, a significant improvement from a net loss of $20.2 million in the prior year's second quarter. However, for the six months ended June 30, 2017, the company reported a net loss of $38.8 million. The company continues to invest heavily in research and development and selling, general, and administrative expenses to support growth, and anticipates that losses may continue as it scales its commercialization and R&D activities. They believe their current resources are sufficient to fund operations through at least June 30, 2018.

The company increased its spending in Research and Development by $9.0 million in Q2 2017 (to $45.3 million) and in Selling, General, and Administrative expenses by $16.5 million (to $85.8 million) compared to the prior year's quarter. These increases are primarily attributed to higher salaries, bonus and payroll-related costs due to increased headcount, additional marketing costs to support revenue growth, and increased R&D spending on equipment and clinical trials for future products.